Source-grounded facts extracted from Teladoc Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Teladoc Health, Inc. reported the three months ended March 31, 2026 ("First Quarter 2026") results: revenue $613.8 million, net income $63.8 million, or $0.36 per share, EPS $0.36 per share. Guidance reaffirmed.
“First Quarter 2026 revenue of $613.8 million, down 2% year-over-year • First Quarter 2026 net loss of $63.8 million, or $0.36 per share”
Teladoc Health, Inc. incurred revolving credit of $300 million with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR plus a margin of 2.75% to 3.25% per annum maturing the fifth anniversary of the Effective Date.
“On July 17, 2025 (the “Effective Date”), Teladoc Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), issuing bank and swingline lender, and the lenders party thereto. The Credit Agreement provides for a five-year, $300 million senior secured revolving credit facility (the “Revolving Credit Facility”).”
Michael Waters resigned as Chief Operating Officer at Teladoc Health, Inc..
“On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure.”
Joseph Catapano was appointed as Senior Vice President and Chief Accounting Officer at Teladoc Health, Inc..
“Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer.”
Laizer Kornwasser departed as President, Enterprise Growth and Global Markets at Teladoc Health, Inc..
“On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024.”
Mala Murthy changed role as Chief Financial Officer at Teladoc Health, Inc..
“Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer.”
Charles Divita, III was appointed as Director at Teladoc Health, Inc..
“appointed Mr. Divita as a director of the Company.”
Charles Divita, III was appointed as Chief Executive Officer at Teladoc Health, Inc..
“Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer.”
Teladoc Health, Inc. reported three months ended March 31, 2024 results: revenue $646.1 million, net income $81.9 million net loss, EPS $0.49 per share. Guidance reaffirmed.
“the three months ended March 31, 2023 (“First Quarter 2023”). Financial and Operational Highlights for First Quarter 2024 • First Quarter 2024 revenue grows 3% year-over-year to $646.1 million • First Quarter 2024 net loss of $81.9 million, or $0.49 per share • First Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year “We are pleased to report a solid”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.